Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Evidence level: registry entry; no results posted
A registered phase 1 trial (SIMILAR) of fostamatinib versus placebo in lung transplant recipients with donor-specific antibodies, sponsored by NHLBI.
As of . Primary source: ClinicalTrials.gov NCT06948097.
Summary
The ClinicalTrials.gov entry describes SIMILAR as a randomised, double-blind, placebo-controlled, dose-escalation phase 1 trial of fostamatinib, with 30 participants estimated, in adults who developed donor-specific antibodies after a lung transplant. The registry lists the primary outcome as the study drug discontinuation rate. The registry condition field reads "Lung Transplantation"; chronic lung allograft dysfunction is not listed as a condition. The entry was last updated on 9 October 2026 and gives an estimated start date of 14 October 2026. No results are posted.
Details
- registry
- ClinicalTrials.gov
- registryId
- NCT06948097
- registryTitle
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies.
- sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- registryStatus
- recruiting
- phase
- Phase 1
- studyType
- interventional
- enrolment
- 30 (estimated)
- startDate
- 2026-10-14 (estimated)
- primaryCompletionDate
- 2028-07-14 (estimated)
- intervention
- fostamatinib (drug); Placebo (drug)
- condition
- Lung Transplantation
- registryLastUpdatePosted
- 2026-10-09
- registryRead
- 2026-10-10
Sources and links
Related
Linked from (derived)
Known gaps in this record
- acronym: not shown in the registry entry
- results: none posted in the registry
- participating centres and investigators: not recorded
- link to a CLADsolve centre record: not made
- relation to CLAD: the registry condition is "Lung Transplantation" (donor-specific antibodies); CLAD is not named
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.